Discovery
Candidate selection runs against a structural library and an in-house assay panel. Most things fail here, which is the point.
The platform that carries a molecule through discovery, characterisation and manufacture.
The Adjuvant Bio antibody platform pairs computational structure modelling with high-throughput screening to engineer monoclonal antibodies for binding affinity, stability, and manufacturability.
Host cell lines tuned for high-yield, stable expression of complex glycoproteins, with titers exceeding 8 g/L in fed-batch culture.
Predictive models screen thousands of candidates in days, scoring immunogenicity and developability before a lead is committed.
Upstream and downstream processing designed to meet global GMP and regulatory standards across target markets.
Where each programme sits against the regulatory pathway, what gates it next, and when the data is expected. Partnered programmes are run with a co-development sponsor; platform programmes carry technology that later portfolio entries inherit.
The same platform carries a molecule through discovery, into a characterised process, and out to a line that can run it every week.
Candidate selection runs against a structural library and an in-house assay panel. Most things fail here, which is the point.
Higher-order structure, glycan profile, and impurity fate are pinned down before a process is locked. A biosimilar is only as good as the analytics behind it.
The locked process moves to a line that reproduces it batch after batch, under one quality system and one set of release specifications.
Proprietary CHO lines selected for titre, stability and glycan profile.
Perfusion-ready upstream and single-use downstream, designed to scale.
Higher-order structure, impurity fate and comparability, pinned down.